Cart
sales@molnova.com
Natalizumab
CAS No. 189261-10-7
Natalizumab( —— )
Catalog No. M23864 CAS No. 189261-10-7
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 218 | In Stock |
|
| 5MG | 392 | In Stock |
|
| 10MG | 629 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1237 | In Stock |
|
| 100MG | 1665 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNatalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
Recptorα4β1 integrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number189261-10-7
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.
molnova catalog
related products
-
A 286982
A 286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.
-
RO0270608
RO0270608, the active metabolite of R411, is an orally active dual α4β1/α4β7 integrin antagonist with anti-inflammatory properties, useful for studying allergic inflammatory responses.
-
OSU-T315 (15-regiois...
OSU-T315 (15-regioisomer) is a ILK inhibitor.
